adalimumab Articles
NICE OK's Abbott Labs' Humira for PA
3 September 2007
Abbott Labs' 2nd-qtr 2007 profit soars 61.4%
23 July 2007
Humira improves work performance in RA patients
25 June 2007
Humira gets EU OK for severe Crohn's
18 June 2007
Stock Commentary - New York week to May 28, 2007
4 June 2007
Peptech's six-month profits soar to $133M
28 May 2007
Royalty Pharma buys stake in Remicade IP
14 May 2007
Abbott files Humira for childhood RA and IA
14 May 2007
Peptech to buy EvoGenix for $129M
14 May 2007
Abbott's Humira gets CHMP nod for Crohn's
7 May 2007
Abbott's 1st-qtr profit drops 19% to $697.5M
23 April 2007
Abbott opens Humira plant in Puerto Rico
16 April 2007
Abbott seeks approval for Humira in psoriasis
9 April 2007
Japan stock market week to March 19, 2007
26 March 2007
Stock Commentary - New York week to March 5, 2007
12 March 2007
Abbott
5 March 2007
Abbott's Humira effective as psoriasis therapy
12 February 2007
Abbott suffers 4th-qtr $0.37 LPS on Kos buy
5 February 2007
RA biological competitors spent $195M on promotion
8 January 2007
Anti-TNF drug sales to hit $1.3B by 2015
22 December 2006
Merck & Co switches DTC marketing focus
11 December 2006
Abbott's Humira gets expanded US label
20 November 2006
Abbott's Humira granted priority review for CD
6 November 2006
Humira superior to MTX in psoriasis study
16 October 2006
Blockbuster status forecast for Enbrel by 2010
18 September 2006
Abbott files Humira for CD in USA and EU
18 September 2006
Devgen sees good data in trials of oral TNF inhibitors
28 August 2006
Abbott's Humira gets FDA OK for AS
7 August 2006
Abbott's 2nd qtr profit drops on Guidant buy
24 July 2006
Humira in AS discussed at EULAR congress
3 July 2006
Abbott's Humira gets EU OK for AS
19 June 2006
CAT's profits hit L4.6M for six month to March
29 May 2006
Strong RA data for Abbott's Humira + MTX
15 May 2006
Abbott's new Kaltera tablet gets CHMP's OK
8 May 2006
CAT 1st-qtr revenue reached L14M
13 February 2006
Abbott:13.4% 4th-qtr 2005 EPS growth, as expected
6 February 2006
Japan stock market 3 weeks to Jan 2, 2006
9 January 2006
CAT's fiscal year results beat forecasts
5 December 2005
Cambridge Antibody Technology's 9-mth loss narrows; lower 3rd-qtr litigation costs
19 September 2005
US FDA advisers urge appro of B-MS' Orencia
12 September 2005
Abbott UK: "growth of 70% in next five years"
27 June 2005
Humira boosts QoL in psoriatic arthritis
20 June 2005
Abbott's Humira/MTX: good long-term outcome
20 June 2005
Humira: strong results against Crohn's disease
30 May 2005
Japan stock market week to April 18
25 April 2005
Abbott gets leave of appeal on CAT royalty decision
28 March 2005
Abbot's Humira gives promising psoriasis results
28 February 2005
Cambridge Antibody projects lower cash burn, break-even in 2007/8?
14 February 2005
Stock Commentary - Europe
7 February 2005
Abbott's RA drug Humira a potential therapy for Crohn's disease?
7 February 2005
Stock Commentary - Europe
10 January 2005
Abbott submits Humira filings for RA
10 January 2005
CAT prevails in Humira royalty dispute with Abbott
10 January 2005
Abbott's Humira filed for new use in USA and EU
10 January 2005
Stock Commentary - Europe - week to Oct 4
11 October 2004
FDA OKs expanded use of Abbott's Humira
16 August 2004
Abbott's 2nd-qtr 2004 sales rise 14%
19 July 2004
CAT sues Abbott over Humira royalties dispute
24 May 2004
CAT sees net loss slip 4.3% for first half
24 May 2004
Abbott sees 13.9% rise in sales for 1st-qtr 2004
19 April 2004
Abbott's Humira shows promise for psoriasis
23 February 2004
CAT-192 is safe but efficacy in doubt
16 February 2004
Abbott reports sharp rise in 4-qtr profit
26 January 2004
Abbott Labs' Humira marks first successful year
5 January 2004
UPDATE - Celltech shares plunge on Pfizer decision, big pharma tough on UK biotechs
24 November 2003
CAT takes Abbott to court over Humira
24 November 2003
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
CAT in Humira dispute
20 October 2003
Abbott files for new Humira indication
13 October 2003
CAT and Dyax expand licensing deal
29 September 2003
Stock Commentary - New York
22 September 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
